Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. … Read more
Restart Life Sciences Corp. (NMLSD) - Total Assets
Latest total assets as of June 2025: $277.56K USD
Based on the latest financial reports, Restart Life Sciences Corp. (NMLSD) holds total assets worth $277.56K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Restart Life Sciences Corp. - Total Assets Trend (2020–2024)
This chart illustrates how Restart Life Sciences Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Restart Life Sciences Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
Restart Life Sciences Corp.'s total assets of $277.56K consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.9% |
| Accounts Receivable | $11.37K | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Restart Life Sciences Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Restart Life Sciences Corp.'s current assets represent 95.2% of total assets in 2024, an increase from 84.7% in 2020.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2024, down from 70.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Restart Life Sciences Corp. Competitors by Total Assets
Key competitors of Restart Life Sciences Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Restart Life Sciences Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Restart Life Sciences Corp. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Restart Life Sciences Corp. generates $ 118.04 in net profit.
Restart Life Sciences Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 0.02 | 0.06 |
| Quick Ratio | 1.25 | 0.02 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $54.51K | $ -1.06 Million | $ -613.16K |
Restart Life Sciences Corp. - Advanced Valuation Insights
This section examines the relationship between Restart Life Sciences Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 513.0% |
| Total Assets | $190.40K |
| Market Capitalization | $539.72 USD |
Valuation Analysis
Below Book Valuation: The market values Restart Life Sciences Corp.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Restart Life Sciences Corp.'s assets grew by 513.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Restart Life Sciences Corp. (2020–2024)
The table below shows the annual total assets of Restart Life Sciences Corp. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $190.40K | +513.02% |
| 2023-12-31 | $31.06K | -89.53% |
| 2022-12-31 | $296.79K | -66.32% |
| 2021-12-31 | $881.16K | -71.08% |
| 2020-12-31 | $3.05 Million | -- |